Company Shares of Novartis AG (NYSE:NVS) Drops by -0.7%

Novartis AG (NYSE:NVS) has risen sharply, recording gains of 4.04% in the past 4 weeks. However, the stock has corrected -0.7% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 2.39% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

The company shares have dropped -21.11% from its 1 Year high price. On Jul 20, 2015, the shares registered one year high at $106.84 and the one year low was seen on Apr 1, 2016. The 50-Day Moving Average price is $79.67 and the 200 Day Moving Average price is recorded at $77.24.

The stock has recorded a 20-day Moving Average of 3.37% and the 50-Day Moving Average is 5.1%.


Novartis AG (NYSE:NVS): stock turned positive on Friday. Though the stock opened at $81.63, the bulls momentum made the stock top out at $82.32 level for the day. The stock recorded a low of $81.53 and closed the trading day at $82.13, in the green by 0.40%. The total traded volume for the day was 1,134,654. The stock had closed at $81.8 in the previous days trading.

Novartis AG is a holding company that, through its subsidiaries, is engaged in development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals around the world. Its portfolio includes medicines, eye care, generic pharmaceuticals, preventive vaccines and over-the-counter (OTC) products. The Companys segments include Pharmaceuticals, which include patent-protected prescription medicines; Alcon, which include surgical, ophthalmic pharmaceutical and vision care products; Sandoz, which include generic pharmaceuticals, and Consumer Health, which includes the OTC Division. Pharmaceuticals products include Afinitor/Votubia, Exjade, Galvus, Exforge and Voltaren, among others. Its Sandoz products include Valsartan (Diovan), Cyclophosphamide injection and AirFluSal Forspiro, among others. Its OTC offers readily available consumer medicine. The Company operates Admune Therapeutics as a wholly owned subsidiary.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.